Literature DB >> 23677748

Mood disturbance in glioma patients.

A A Acquaye1, E Vera-Bolanos, T S Armstrong, M R Gilbert, L Lin.   

Abstract

Patients diagnosed with primary brain tumors such as glioma experience psychological distress throughout the illness trajectory. Determining which patient characteristics are associated with more severe mood disturbance throughout the illness trajectory can help identify patients at risk and assist in developing targeted interventions based on these factors. Adult glioma patients were eligible for participation. Data collection tools included an investigator completed clinician assessment tool, patient completed demographic form and the Profile of mood states-short form. A multiple regression model was used to describe the relationship between the patient groups and clinical factors. The study enrolled 186 glioma patients of various tumor grades, who were categorized in three groups (newly diagnosed, on-treatment, follow-up) based on disease status at time of visit. Newly diagnosed patients experienced more total mood disturbance than all the other groups. Characteristics associated with more severe mood disturbance varied by patient group: newly diagnosed patients who were not on corticosteroids and were not married were more likely to have higher mood disturbance [R(2) = 0.27, F (2, 29) = 5.31, p < 0.02]. For those on treatment, the use of concomitant medications, having more than 1 recurrence and low income predicted higher mood disturbance [R(2) = 0.417, F (4, 67) = 11.98, p < 0.001]. For those not on active treatment, female sex, anti-depressant use and having a lower income was associated with higher mood disturbance [R(2) = 0.183, F (3, 55) = 4.11, p < 0.02]. Additionally, when compared to other cancer groups, glioma patients reported similar mood disturbance to those with breast cancer. Factors other than disease characteristics are associated with higher mood disturbance and vary according to current disease status. The use of concomitant medications, demographic factors, recurrence and income are associated with mood disturbance and interventions may need to be tailored to these underlying factors.

Entities:  

Mesh:

Year:  2013        PMID: 23677748     DOI: 10.1007/s11060-013-1143-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

Review 2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

3.  Impact of the cost of cancer treatment: an internet-based survey.

Authors:  Maurie Markman; Ryan Luce
Journal:  J Oncol Pract       Date:  2010-02-19       Impact factor: 3.840

4.  Psychological adjustment to gynaecological cancer: patients' illness representations, coping strategies and mood disturbance.

Authors:  Rachel V Gould; Stephen L Brown; Ros Bramwell
Journal:  Psychol Health       Date:  2010-06

5.  Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

Authors:  T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

Review 6.  Depression in cerebral glioma patients: a systematic review of observational studies.

Authors:  Alasdair G Rooney; Alan Carson; Robin Grant
Journal:  J Natl Cancer Inst       Date:  2010-11-24       Impact factor: 13.506

Review 7.  Relationship between cancer and psychology: an updated history.

Authors:  C M Conti; D Angelucci; M Ferri; G Maccauro; A Caraffa; R Doyle; M Fulcheri; E Cianchetti
Journal:  J Biol Regul Homeost Agents       Date:  2011 Jul-Sep       Impact factor: 1.711

8.  No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial.

Authors:  Nina Rottmann; Susanne Oksbjerg Dalton; Pernille Envold Bidstrup; Hanne Würtzen; Mette Terp Høybye; Lone Ross; Jane Christensen; Kirsten Frederiksen; Dorte Gilså Hansen; Christoffer Johansen
Journal:  Psychooncology       Date:  2011-02-08       Impact factor: 3.894

9.  Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma.

Authors:  Alasdair G Rooney; Shanne McNamara; Mairi Mackinnon; Mary Fraser; Roy Rampling; Alan Carson; Robin Grant
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

10.  Predicting major depression in brain tumor patients.

Authors:  David K Wellisch; Thomas A Kaleita; Donald Freeman; Timothy Cloughesy; Jeffrey Goldman
Journal:  Psychooncology       Date:  2002 May-Jun       Impact factor: 3.894

View more
  8 in total

1.  Hope and mood changes throughout the primary brain tumor illness trajectory.

Authors:  Alvina A Acquaye; Lin Lin; Elizabeth Vera-Bolanos; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2015-06-23       Impact factor: 12.300

Review 2.  Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.

Authors:  Terri S Armstrong; Allison M Bishof; Paul D Brown; Martin Klein; Martin J B Taphoorn; Christina Theodore-Oklota
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

Review 3.  Use of virtual reality for symptom management in solid-tumor patients with implications for primary brain tumor research: a systematic review.

Authors:  Nicole M Leggiero; Terri S Armstrong; Mark R Gilbert; Amanda L King
Journal:  Neurooncol Pract       Date:  2020-03-28

Review 4.  Symptom management and quality of life in glioma patients.

Authors:  Florien W Boele; Martin Klein; Jaap C Reijneveld; Irma M Verdonck-de Leeuw; Jan J Heimans
Journal:  CNS Oncol       Date:  2014-01

Review 5.  Sleep-wake disturbance in patients with brain tumors.

Authors:  Terri S Armstrong; Marcia Y Shade; Ghislain Breton; Mark R Gilbert; Anita Mahajan; Michael E Scheurer; Elizabeth Vera; Ann M Berger
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

6.  Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.

Authors:  Sheng Han; Lingxuan Meng; Yang Jiang; Wen Cheng; Xinxin Tie; Junzhe Xia; Anhua Wu
Journal:  Br J Cancer       Date:  2017-03-30       Impact factor: 7.640

7.  Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study.

Authors:  James L Rogers; Elizabeth Vera; Alvina Acquaye; Nicole Briceno; Varna Jammula; Amanda L King; Heather Leeper; Martha M Quezado; Javier Gonzalez Alarcon; Lisa Boris; Eric Burton; Orieta Celiku; Anna Choi; Alexa Christ; Sonja Crandon; Ewa Grajkowska; Nicole Leggiero; Nicole Lollo; Marta Penas-Prado; Jennifer Reyes; Christine Siegel; Brett J Theeler; Michael Timmer; Kathleen Wall; Jing Wu; Kenneth Aldape; Mark R Gilbert; Terri S Armstrong
Journal:  Neurooncol Pract       Date:  2021-04-10

Review 8.  End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective.

Authors:  Giuseppe Roberto Giammalva; Domenico Gerardo Iacopino; Giorgio Azzarello; Claudia Gaggiotti; Francesca Graziano; Carlo Gulì; Maria Angela Pino; Rosario Maugeri
Journal:  Brain Sci       Date:  2018-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.